![BeiGene, Ltd. Website](https://cdn.finchat.io/115205344.png)
BeiGene, Ltd.
NasdaqGS-BGNE
Company Overview
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Name
BeiGene, Ltd.
CEO
Mr. John V. Oyler
Website
www.beigene.com
Sector
Biotechnology
Year Founded
2010
Profile
Market Cap
$20.33B
EV
$18.82B
Shares Out
106.24M
Revenue
$3,096.54M
Employees
10,000
Margins
Gross
84.98%
EBITDA
-25.71%
Operating
-28.65%
Pre-Tax
-15.2%
Net
-16.91%
FCF
-41.51%
Returns (5Yr Avg)
ROA
-29.12%
ROTA
-42.07%
ROE
-41.78%
ROCE
-36.47%
ROIC
-138.94%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$272.96
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$2,592.66M
Net Debt
-$1,502.67M
Debt/Equity
0.32
EBIT/Interest
-242.9
Growth (CAGR)
Rev 3Yr
48.42%
Rev 5Yr
48.14%
Rev 10Yr
71.53%
Dil EPS 3Yr
-30.06%
Dil EPS 5Yr
-14.98%
Dil EPS 10Yr
23.01%
Rev Fwd 2Yr
35.8%
EBITDA Fwd 2Yr
—
EPS Fwd 2Yr
—
EPS LT Growth Est
-38.66%
Dividends
Yield
—
Payout
—
DPS
—
DPS Growth 3Yr
—
DPS Growth 5Yr
—
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
—